7-Eleven ceases ephedra sales
This article was originally published in The Tan Sheet
Most of 7-Eleven's 3,200-plus franchisees have stopped selling products containing ephedrine alkaloids due to company policy not to provide product liability insurance coverage for franchisees marketing and selling the supplements, firm says. Policy took effect Nov. 1. Convenience store chain reported Dec. 11 it is in talks "with several manufacturers on ephedra-free products that will meet the needs of our consumers who are looking for safe...ways to lose weight." Metabolife supplements were the main ephedra products sold at 7-Eleven, according to the retailer...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.